| Dr Jensi Nicole Parker, PHARM D | |
|
760 Hospital Circle, Browning, MT 59417 | |
| (406) 338-8908 | |
| Not Available |
| Full Name | Dr Jensi Nicole Parker |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 760 Hospital Circle, Browning, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932585148 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 18794 (Alabama) | Primary |
| 183500000X | Pharmacist | E-14010 (Mississippi) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jensi Nicole Parker, PHARM D 212 Lanoah Ln, Brandon, MS 39042-7897 Ph: (406) 338-8908 | Dr Jensi Nicole Parker, PHARM D 760 Hospital Circle, Browning, MT 59417 Ph: (406) 338-8908 |
News Archive
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.
Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.
The opportunistic fungal pathogen Candida albicans inconspicuously lives in our bodies until it senses that we are weak, when it quickly adapts to go on the offensive. The fungus, known for causing yeast and other minor infections, also causes a sometimes-fatal infection known as candidemia in immunocompromised patients. An in vivo study, published in mBio, demonstrates how C. albicans can distinguish between a healthy and an unhealthy host and alter its physiology to attack.
A new study from the Swedish medical university Karolinska Institutet shows that asthma drugs are a potential treatment for aortic aneurysm. These drugs, which block cysteinyl-leukotrienes, could reduce the break down of vessel wall tissue and the dilation of the aortic wall, and thus the risk of its rupturing.
› Verified 8 days ago
Kenneth Jacob Craig, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 760 Hospital Drive, Browning, MT 59417 Phone: 406-338-8908 Fax: 406-338-6351 | |
Hieu Tran, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 760 Hospital Circle, Browning, MT 59417 Phone: 407-338-8908 | |
Mr. Gary D. Baker, RPH, MBA Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 760 Hospital Ave., Pharmacy Department, Browning, MT 59417 Phone: 406-338-6108 Fax: 406-338-6351 | |
Mr. Cory Thomas Poulton, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 760 Hospital Dr, Browning, MT 59417 Phone: 406-338-8908 | |
Rick Anderton, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 760 Hospital Circle, Browning, MT 59417 Phone: 406-338-6101 Fax: 406-338-6351 | |
Mr. Harry Ray Pitcher, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 760 Hospital Dr, Browning, MT 59417 Phone: 406-338-6110 | |
Brian Hall, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 760 Hospital Circle, Browning, MT 59417 Phone: 406-338-8908 Fax: 406-338-6351 |